Of these, 13 drugs induced significant 125I uptake in thyroid cancer cells stably expressing NIS as well as in human primary thyrocytes, implicating targeting of pathways which control normal physiological NIS function (Table 1). This evidence concerns the gene SLC5A5 and thyroid cancer.